Publications by authors named "Luisa M Reyes-Cortes"
One-Step Bioprinting of Multi-Channel Hydrogel Filaments Using Chaotic Advection: Fabrication of Pre-Vascularized Muscle-Like Tissues.
Adv Healthc Mater
December 2022
Article Synopsis
- Biofabrication of living tissues with hollow channels is essential for creating thicker tissues, but traditional methods struggle with channels smaller than hundreds of micrometers.! -
- The study introduces a new technique using co-extrusion of cell-laden hydrogels and sacrificial materials to produce thin filaments (1 mm in diameter) with tiny channels that improve cell growth and alignment.! -
- Results show that these hollow channels enhance cell viability, promote muscle-specific markers, and lead to better tissue engineering outcomes, providing a promising method for developing pre-vascularized tissues.!
Cancer continues to be a leading cause of mortality in modern societies; therefore, improved and more reliablecancer models are needed to expedite fundamental research and anti-cancer drug development. Here, we describe the use of a miniaturized continuous stirred tank reactor (mCSTR) to first fabricate and mature cancer spheroids (i.e.
View Article and Find Full Text PDFComplete Screening of Exons 2, 3, and 4 of KRAS and NRAS Genes Reveals a Higher Number of Clinically Relevant Mutations than Food and Drug Administration Quantitative Polymerase Chain Reaction-Based Commercial Kits.
Rev Invest Clin
December 2020
Background: The presence of clinically relevant mutations in KRAS and NRAS genes determines the response of anti-epidermal growth factor receptor antibody therapy for metastatic colorectal cancer (mCRC). The only quantitative polymerase chain reaction (qPCR)-based diagnostic tests approved by the Food and Drug Administration (FDA) screen merely for mutations in codons 12 and 13 of KRAS.
Objective: The objective of the study was to study the frequency of clinically relevant mutations in KRAS and NRAS genes that are not included in FDA-approved qPCR tests.
The treatment of Type 2 Diabetes Mellitus (T2DM) consists primarily of oral antidiabetic drugs (OADs) that stimulate insulin secretion, such as sulfonylureas (SUs) and reduce hepatic glucose production (e.g., biguanides), among others.
View Article and Find Full Text PDFBackground: Current metastatic colorectal cancer (mCRC) therapy uses monoclonal antibodies against the epidermal growth factor receptor. This treatment is only useful in the absence of K-RAS gene mutations; therefore the study of such mutations is part of a personalized treatment. The aim of this work is to determine the frequency and type of the most common K-RAS mutations in Mexican patients with metastatic disease by nucleotide sequencing.
View Article and Find Full Text PDF